This is a routine governance filing with no material financial or operational implications. Monitor for any future board changes or strategic shifts, but no immediate trading action is warranted.
Price Chart
Executive Summary
Vir Biotechnology filed an 8-K reporting the departure of board member and Audit Committee Chair Saira Ramasastry due to a business conflict, effective May 26, 2026, with no disagreement with the company. The board reduced its size from eight to seven members and appointed Robert More as Audit Committee Chair. The filing also summarizes the 2026 Annual Meeting results, where all three Class I director nominees were elected, the advisory vote on executive compensation passed, and Ernst & Young was ratified as auditor.
Key Facts
- Director Saira Ramasastry stepped down from the board and Audit Committee effective May 26, 2026, due to a business conflict, not due to any disagreement with the company.
- Board size reduced from eight to seven members.
- Robert More appointed as Audit Committee Chair.
- At the 2026 Annual Meeting, all three Class I director nominees (Robert More, Janet Napolitano, Elliott Sigal) were elected.
- Advisory vote on executive compensation passed with 108,453,963 votes for, 11,863,405 against, and 1,372,563 abstentions.
- Ratification of Ernst & Young as independent auditor passed with 137,048,756 votes for, 153,836 against, and 1,164,682 abstentions.
- 161,234,058 shares were outstanding and entitled to vote as of the March 31, 2026 record date.
Financial Impact
No financial impact from this filing.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-038630 |
| Document: 0001628280-26-038630-index-headers.html | 0001628280-26-038630 |
| Document: 0001628280-26-038630-index.html | 0001628280-26-038630 |
| Document: 0001628280-26-038630.txt | 0001628280-26-038630 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Court Ruling | $9.24 $9.78 | ▲ +5.84% | ▲ +7.21% | $11.17 (+20.89%) |
Aug 9, 2026 7w ago | Institutional Cluster | $8.89 $9.39 | ▲ +5.62% | ▲ +5.67% | $11.17 (+25.65%) |
Jul 24, 2026 10w ago | 8-K | $8.69 $8.90 | ▲ +2.42% | ▲ +2.04% | $11.17 (+28.54%) |
Jun 29, 2026 13w ago | 144 | $10.38 $10.02 | ▼ −3.47% | ▼ −4.86% | $11.17 (+7.61%) |
Jun 10, 2026 16w ago | 3 | $8.52 $9.30 | ▲ +9.15% | ▲ +8.72% | $11.17 (+31.10%) |
Jun 10, 2026 16w ago | 8-K | $8.52 $9.30 | ▲ +9.15% | ▲ +8.72% | $11.17 (+31.10%) |
Jun 2, 2026 17w ago | Insider Cluster | $8.77 $8.25 | ▼ −5.93% | ▼ −2.11% | $11.17 (+27.37%) |
May 28, 2026 18w ago | 8-K | $9.55 $8.77 | ▼ −8.17% | ▼ −8.12% | $11.17 (+16.96%) |
Apr 16, 2026 24w ago | DEFA14A | $10.33 $10.35 | ▲ +0.19% | ▼ −0.79% | $11.17 (+8.13%) |
Apr 10, 2026 25w ago | 8-K | $9.31 $11.09 | ▲ +19.12% | ▲ +15.82% | $11.17 (+19.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access